Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA's China Staff Increase Takes Hold As Gottlieb Boosts Border Security

Executive Summary

After receiving delayed visas, additional FDA is inspectors and other staff can relocate to China office; Gottlieb also announces increase in international mail facility staff.

You may also be interested in...



US FDA's Brexit: One Staffer Moving, But Impact Still May Loom Large

Uncertainty about Brexit's impact on the FDA-EMA mutual recognition agreement are among issues worrying regulators as countdown continues to the UK's departure from the EU.

Gottlieb Showing Capitol Hill Skills With Funding Success

US FDA gains $94m in new funding for international mail facilities, a priority for the commissioner, along with an increase in non-user fee dollars for agency operations.

Gottlieb's Priority For Proposed Opioid Money Is Mail Facilities

US FDA commissioner says primary use of proposed budget boost would be border security; budget documents state that special opioid epidemic funding also would support regulatory science and diagnostic development.

Related Content

Topics

UsernamePublicRestriction

Register

PS121320

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel